Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Prelude Therapeutics (PRLD) Accumulated Depreciation & Amortization (2023 - 2025)

Prelude Therapeutics' Accumulated Depreciation & Amortization history spans 3 years, with the latest figure at $6.9 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 31.78% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.9 million, a 31.78% increase, with the full-year FY2025 number at $6.9 million, up 31.78% from a year prior.
  • Accumulated Depreciation & Amortization hit $6.9 million in Q4 2025 for Prelude Therapeutics, up from $5.3 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for PRLD hit a ceiling of $6.9 million in Q4 2025 and a floor of $3.6 million in Q4 2023.
  • Historically, Accumulated Depreciation & Amortization has averaged $5.3 million across 3 years, with a median of $5.3 million in 2024.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 47.45% in 2024 and later skyrocketed 31.78% in 2025.
  • Tracing PRLD's Accumulated Depreciation & Amortization over 3 years: stood at $3.6 million in 2023, then skyrocketed by 47.45% to $5.3 million in 2024, then surged by 31.78% to $6.9 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for PRLD at $6.9 million in Q4 2025, $5.3 million in Q4 2024, and $3.6 million in Q4 2023.